News

Filter

1 to 9 of 798 results

Batch of mixed NICE decisions for Xarelto, Imnovid, Jardiance and Targaxan

25-03-2015

The National Institute of Health and Care Excellence (NICE), the medicines cost watchdog for England…

BayerBoehringer IngelheimCardio-vascularCelgene CorpDiabetesImnovidJardianceNephrology and HepatologyNorgineOncologyPharmaceuticalTargaxanUKXarelto

Costs and consequences of not treating high cholesterol in the USA

23-03-2015

High cholesterol itself is not a disease, but it can lead to serious health consequences, according to…

Cardio-vascularFinancialHealthcarePharmaceuticalUSA

AstraZeneca’s Brilinta reduced thrombotic CV events in patients with history of heart attack

16-03-2015

Anglo-Swedish pharma major AstraZeneca released much anticipated trial results for its blood-thinning…

AstraZenecaBrilintaCardio-vascularFinancialPharmaceuticalResearch

Amgen and Sanofi/Regeneron's PCSK9 inhibitors halve risk of cardiovascular events

Amgen and Sanofi/Regeneron's PCSK9 inhibitors halve risk of cardiovascular events

16-03-2015

Results of a new study published in the New England Journal of Medicine have shown that the experimental…

AmgenCardio-vascularPharmaceuticalPraluentRegeneronResearchSanofi

AstraZeneca undertakes two-year collaboration with Singaporean organizations for heart failure

AstraZeneca undertakes two-year collaboration with Singaporean organizations for heart failure

11-03-2015

Anglo-Swedish drug major AstraZeneca is to undertake a two-year collaboration with leading organizations…

AstraZenecaCardio-vascularPharmaceuticalResearchSingapore

NICE draft guidance recommends Eliquis for treating and preventing potentially fatal blood clots

NICE draft guidance recommends Eliquis for treating and preventing potentially fatal blood clots

06-03-2015

In draft guidance published today, the National Institute for Health and care Excellence (NICE), the…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPricingRegulationUK

Atrial fibrillation market to double by 2020 before steep decline

Atrial fibrillation market to double by 2020 before steep decline

26-02-2015

The global market for atrial fibrillation treatment will more than double in value between 2013 and 2020,…

Cardio-vascularChemistryMarkets & MarketingMedicineOrganic chemistryPharmaceuticalStroke

Lilly accepts committee recommendation to extend evacetrapib study by six months

Lilly accepts committee recommendation to extend evacetrapib study by six months

20-02-2015

US drug major Eli Lilly has accepted the recommendation of the ACCELERATE study academic executive committee…

Cardio-vascularEli LillyevacetrapibPharmaceuticalResearchUSA

1 to 9 of 798 results

Back to top